Immix Biopharma (NASDAQ:IMMX) Upgraded by Wall Street Zen to “Hold” Rating

Immix Biopharma (NASDAQ:IMMX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other equities analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Mizuho started coverage on Immix Biopharma in a research report on Monday, February 9th. They set an “outperform” rating and a $14.00 target price for the company. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $11.00.

Immix Biopharma Stock Performance

Shares of NASDAQ IMMX opened at $9.29 on Friday. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $9.47. The company has a market cap of $492.00 million, a price-to-earnings ratio of -12.06 and a beta of 0.25. The business’s 50 day moving average price is $6.38 and its 200-day moving average price is $4.47.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Allworth Financial LP purchased a new stake in shares of Immix Biopharma during the fourth quarter valued at $30,000. Velan Capital Investment Management LP purchased a new position in Immix Biopharma in the 2nd quarter worth $52,000. Mathes Company Inc. purchased a new position in Immix Biopharma in the 4th quarter worth $56,000. Balyasny Asset Management L.P. acquired a new stake in Immix Biopharma during the 4th quarter worth about $67,000. Finally, Kera Capital Partners Inc. acquired a new stake in Immix Biopharma during the 4th quarter worth about $68,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.